Gene editing · Wilson disease · First-in-human
First patient dosed with PM577a, Prime Medicine’s first in vivo Prime Editor, in H1069Q Wilson disease
On Oct 5, 2026, Prime Medicine announced the first patient dosed in a global Phase 1/2 trial of PM577a, an LNP-delivered Prime Editor designed to correct the ATP7B H1069Q mutation in hepatocytes with a single IV infusion. This is the company’s first in vivo Prime Editing study. FDA also granted PM577 Rare Pediatric Disease designation. Planned efficacy measures include 64Cu PET copper efflux, ceruloplasmin, non-ceruloplasmin-bound copper and 24-hour urinary copper, and the trial will evaluate stopping baseline standard-of-care therapy.
Caveat: First patient dosed only. There are no efficacy or safety data yet, and it’s a company press release. Initial enrollment is limited to clinically stable adults on standard therapy.
BioSpace / GlobeNewswire →
Neuroscience · Nobel Prize · Optogenetics
2026 Nobel Prize in Physiology or Medicine goes to Deisseroth, Hegemann and Nagel for optogenetics
Announced Oct 5, 2026 by the Nobel Assembly at Karolinska Institutet, the prize recognizes “discoveries concerning light-gated ion channels and optogenetics.” Hegemann and Nagel discovered channelrhodopsin in a single-celled alga, and Deisseroth turned it into a light-controlled switch for neurons (2005), then got it working in living mouse brains two years later. It’s now a core tool for mapping the circuits behind neurological and psychiatric disease.
Caveat: This award is for a research method. Optogenetics is mainly a laboratory tool, and the prize does not imply approved clinical optogenetic therapies.
NobelPrize.org →
Karolinska Institutet →
Genomics · Rare variants · Risk stratification
RovHer prioritizes functional rare missense variants in complex traits (Nature Genetics)
Published Oct 5, 2026, RovHer (rare variant heritability-optimized scores) integrates 75 variant- and gene-level features across about 4.93 million rare variants. Across 21 traits in up to 357,086 UK Biobank European participants, the top 1% of RovHer-ranked missense variants explained an average of 16.1% of rare-variant heritability, about 10 times the 1.2–2.3% from seven alternative methods. It replicated across ancestries and flagged high-risk carriers in 17 monogenic gene–trait pairs.
Caveat: Research tool built mainly on UK Biobank European-ancestry data. It isn’t a validated clinical variant classifier and doesn’t replace ACMG/AMP interpretation.
Nature Genetics →
Aging biology · Multiomics · Twins cohort
Longitudinal multiomics shows personalized aging trajectories (Nature Aging research highlight)
A Nature Aging research highlight published Oct 6, 2026 covers the MultiMuTHER study inside the TwinsUK cohort: 335 women aged 32–80, including monozygotic and dizygotic twin pairs, each with three or more blood draws at least a year apart (median 6 years from first to last visit). All transcriptomic and metabolomic profiling was run together after collection to limit batch effects, and the analysis points to individualized rather than uniform aging trajectories.
Caveat: Observational work in a female-only UK cohort. This is a journal highlight of the underlying study. It isn’t an intervention or a clinically validated aging test.
Nature Aging →
Gene therapy · MPS IIIA · Regulatory
FDA awards a rare pediatric disease priority review voucher for FAYUVI, the first approved MPS IIIA therapy
A Federal Register notice on Oct 6, 2026 confirms FDA issued a priority review voucher to Ultragenyx for FAYUVI (rebisufligene etisparvovec-hopf). It’s an AAV9 gene therapy FDA approved on Sep 17, 2026 for neurologic manifestations of MPS IIIA (Sanfilippo syndrome type A) in children with preserved neurodevelopmental function. Nature Reviews Drug Discovery (Oct 5) notes it’s the first FDA-approved option for the disease.
Caveat: The approved label is narrow (pediatric patients with preserved neurodevelopmental function). The voucher is a regulatory incentive, not new efficacy data. The European MAA is still under review, as covered in the Oct 2 archive edition.
Federal Register →
Nature Reviews Drug Discovery →
